CHRS Coherus BioSciences Inc

Price (delayed)

$1.58

Market cap

$243.71M

P/E Ratio

0.96

Dividend/share

N/A

EPS

$1.64

Enterprise value

$166.58M

?
Relative Growth: Rel. Growth: 69
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 96
Relative Profitability: Rel. Profitability: 88

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings ...

Highlights
Coherus BioSciences's quick ratio has surged by 151% YoY and by 5% QoQ
The equity has soared by 143% YoY and by 29% from the previous quarter

Key stats

What are the main financial stats of CHRS

CHRS stock price

How has the Coherus BioSciences stock price performed over time
Intraday
7.48%
1 week
-4.24%
1 month
-8.67%
1 year
98.24%
YTD
11.27%
QTD
-6.51%

Financial performance

How have Coherus BioSciences's revenue and profit performed over time
Revenue
$46.88M
Gross profit
$31.91M
Operating income
-$171.85M
Net income
$186.27M
Gross margin
68.1%
Net margin
397.3%
The net margin has soared by 196% year-on-year
The revenue rose by 48% year-on-year and by 11% since the previous quarter
The gross profit has grown by 47% YoY and by 13% from the previous quarter
The company's operating margin rose by 35% YoY and by 15% QoQ

Price vs fundamentals

How does CHRS's price correlate with its fundamentals

Growth

What is Coherus BioSciences's growth rate over time

Valuation

What is Coherus BioSciences stock price valuation
P/E
0.96
P/B
3.01
P/S
4.6
EV/EBIT
0.85
EV/EBITDA
0.84
EV/Sales
3.55
Coherus BioSciences's EPS has increased by 15% QoQ
The equity has soared by 143% YoY and by 29% from the previous quarter
The price to book (P/B) is 27% more than the last 4 quarters average of 2.2
The P/S is 48% above the 5-year quarterly average of 2.9
The revenue rose by 48% year-on-year and by 11% since the previous quarter

Efficiency

How efficient is Coherus BioSciences business performance
CHRS's return on equity has dropped by 73% since the previous quarter
The return on assets is up by 19% since the previous quarter

Dividends

What is CHRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CHRS.

Financial health

How did Coherus BioSciences financials performed over time
The total assets is 42% more than the total liabilities
Coherus BioSciences's quick ratio has surged by 151% YoY and by 5% QoQ
The company's total liabilities has shrunk by 66% YoY and by 5% QoQ
The debt is 52% smaller than the equity
The equity has soared by 143% YoY and by 29% from the previous quarter
The debt to equity has soared by 133% YoY but it has contracted by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.